Richard Boehme, PhD, MBA, CMPP
Medical Writer — Antiviral Pharmacology & HCV Cost Translation
Antiviral pharmacologist turned medical communications professional. Bench researcher whose 1988 ganciclovir mechanism paper is still cited in modern textbook and clinical pharmacology reviews. Forty years of moving between molecular biology, regulatory publication, and patient cost translation. ISMPP-credentialed.
The Difference an Antiviral Pharmacologist Makes
Most writing about HIV and HCV medication starts from the prescribing information and works outward. Richard’s writing starts from the molecule and works toward the patient. He spent the early years of the AIDS epidemic at the laboratory bench, characterizing how ganciclovir actually inhibits cytomegalovirus DNA replication — work that produced a 1988 mechanism paper in Reviews of Infectious Diseases still cited nearly four decades later in contemporary pharmacology reviews and structure-based antiviral drug design.
That bench grounding changes what readers get. When Richard explains why bictegravir blocks HIV integration, why sofosbuvir terminates HCV RNA polymerase, or why a licensed generic from Hetero Labs is bioequivalent to a branded product, the explanation rests on direct understanding of viral DNA polymerase inhibition rather than restated package insert language. For SunnyPharma’s HIV cost-access and HCV treatment cost content, that depth lets him write about mechanism, generic equivalence, and treatment-decision logic with the precision the questions deserve.
From the Bench to Publication Practice
Richard earned his PhD in pharmacology with a focus on antiviral drug mechanism, working on the herpesvirus family during the period when the AIDS epidemic was redirecting much of the antiviral research field. His early peer-reviewed publications include the foundational ganciclovir mechanism paper with Thomas Matthews (Reviews of Infectious Diseases, 1988), in vitro and in vivo activity studies of ganciclovir phosphate derivatives against cytomegalovirus (Antiviral Research, 1986), and the discovery of jasplakinolide as a new class of antifungal agent from a marine sponge (Antimicrobial Agents and Chemotherapy, 1988).
Following his bench career, Richard transitioned into medical communications — the specialized writing discipline that converts clinical trial data, regulatory filings, and congress presentations into peer-reviewed manuscripts and patient-facing education. He earned his MBA to understand the commercial side of pharmaceutical publication and his CMPP credential through the International Society for Medical Publication Professionals (ISMPP), the body that defines ethical standards for medical publication practice. His later research interests extended into HIV CCR5 coreceptor tropism testing and HBV viral dynamics.
Today Richard works independently as a medical writer, consultant, and strategic planner, with a particular focus on disease-area medical communications across the pharmaceutical and digital health space. His public commentary covers FDA regulatory enforcement, digital health device classification, and the ethics of health-claim communication — including recent analysis of FDA enforcement action against wearable manufacturers over unapproved health features.
For SunnyPharma he focuses on the antiviral and HCV cost-access content where his pharmacology background does the most work: explaining HIV regimen mechanism, walking patients through what licensed generics actually contain, translating SVR12 cure rates from the HCV trial literature into language patients can apply.
What Richard Contributes to SunnyPharma
Selected Peer-Reviewed Research
Richard has authored or co-authored peer-reviewed antiviral pharmacology research that remains in active citation across modern clinical pharmacology, virology, and structure-based drug design literature. Selected works:
Antiviral Activity and Mechanism of Action of Ganciclovir — Matthews T, Boehme R. Reviews of Infectious Diseases, 1988;10(Suppl 3):S490–S494. View publication ↗
In Vitro and In Vivo Activities of Phosphate Derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-Guanine Against Cytomegaloviruses — Duke AE, Smee DF, Chernow M, Boehme R, Matthews TR. Antiviral Research, 1986;6:299–308.
New Class of Antifungal Agents: Jasplakinolide, a Cyclodepsipeptide From the Marine Sponge, Jaspis Species — Scott VR, Boehme R, Matthews TR. Antimicrobial Agents and Chemotherapy, 1988;32(8):1154–1157.
HIV Coreceptor Tropism and the Phenotypic Trofile Assay — Contributing technical author. Educational materials on CCR5 antagonist medication selection and viral tropism determination prior to treatment.
HBV Viral Dynamics: Dose-Dependent Clearance Modeling — Contributing author. Viral dynamics modeling literature on telbivudine-treated hepatitis B patients and second-phase HBV clearance kinetics.
Long-Term Antiretroviral Therapy in Aging HIV Populations — Contributing author. Conference report and review materials covering drug interactions, comorbidities, and quality-of-life outcomes in long-term ART.
Writing Standards & Editorial Transparency
All content authored or reviewed by Richard Boehme for SunnyPharma is developed in accordance with ICMJE (International Committee of Medical Journal Editors) recommendations, GPP3 (Good Publication Practice 3) guidelines, and the ethical standards of the International Society for Medical Publication Professionals (ISMPP). Richard applies the same regulatory-grade publication discipline he brings to peer-reviewed manuscript development, ensuring every SunnyPharma article is mechanistically accurate, primary-source referenced, and appropriate for a cost-burdened patient audience.
Credentials & Background
PhD in Pharmacology — Antiviral drug mechanism research; bench characterization of ganciclovir and related nucleoside analogues against herpesvirus DNA polymerase.
MBA — Healthcare and pharmaceutical commercialization. Foundation for understanding pricing, payer dynamics, and access economics.
CMPP — Certified Medical Publication Professional — Credential issued by the International Society for Medical Publication Professionals (ISMPP), the body that sets ethical standards for medical publication practice worldwide.
Independent Medical Writer & Consultant — Disease-area medical communications across pharmaceutical and digital health, with ongoing work in publication strategy and regulatory communication.
Public Profile — LinkedIn ↗. Active commentary on FDA regulatory enforcement, digital health, and publication ethics.
Areas of Expertise
Why Richard Writes for SunnyPharma
Richard’s professional career has spanned the full path of an antiviral medication — from molecular characterization at the bench, to clinical trial publication, to the regulatory and commercial decisions that determine whether the medication reaches a patient at a price they can afford. SunnyPharma’s mission sits at the patient-facing end of that path. The bridge from mechanism to access is exactly the bridge his career was built on, and the cost-burdened patient is exactly the reader his pharmacology training was always meant to serve.